Senate Committee Investigates Ozempic and Wegovy Costs - NYT
Tweet
Share
E-mail
Get Alerts NVO Hot Sheet
Join SI Premium – FREE
(Updated - April 24, 2024 12:04 PM EDT)
Senate Committee Investigates Ozempic and Wegovy Costs - NYT
- Senator Bernie Sanders is pressing Novo Nordisk (NYSE: NVO) for details on its pricing of the popular diabetes and weight loss medications.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- Hims & Hers CEO pushes back against FTC suit, says "we are active disruptors"
- Citadel has shed over 80% of aggregate risk from Situational Awareness portfolio - CNBC
Create E-mail Alert Related Categories
Politics, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
